Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ARCAS

Financiado

Cerrado

ARCAS Analysis of the Route to Commercialisation of MVA based influenza vaccin...

ARCAS Analysis of the Route to Commercialisation of MVA based influenza vaccines ARCAS will investigate the commercial potential and commercialization strategy of a platform of continuously updated repository of pandemic influenza vaccine candidates that was developed under the ERC project FLUPLAN. This platfo... ver más

30/11/2013

ERASMUS MC

164K€

Presupuesto del proyecto: 164K€

Líder del proyecto

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-11-30 No tenemos la información de la convocatoria

0% 91% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ERASMUS MC

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FLUNIVAC InFLUenza virus UNIVersal VACcine development program 7M€ Cerrado

FLUTCORE Development of a universal influenza vaccine based on tandem... 4M€ Cerrado

OSIRIX Revolutionary vaccines to prevent pandemic and seasonal outb... 4M€ Cerrado

VACCELERAID A novel vaccine technology leading to accelerated availabili... 71K€ Cerrado

FLUniversal Intranasal, rapid-acting vaccine for all seasonal and pandem... 8M€ Cerrado

FLU-MAL VLP Chimeric Influenza VLP used as vaccine platform for presenta... 194K€ Cerrado

Líder del proyecto

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 164K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto ARCAS will investigate the commercial potential and commercialization strategy of a platform of continuously updated repository of pandemic influenza vaccine candidates that was developed under the ERC project FLUPLAN. This platform is based on a novel vector technology using recombinant modified vaccinia virus Ankara (MVA) to develop pandemic influenza vaccines. There are two major advantages of the platform in comparison to current pandemic influenza vaccine platforms using adjuvanted-inactivated and live-attenuated influenza vaccines: i) the high immunogenicity induced in the absence of adjuvants, even at very low dosages, and ii) higher and faster vaccine production capacity. This addresses today’s key unmet needs of pandemic influenza vaccines: strong and broad immunogenicity as well as virtually unlimited production capacity for large scale vaccination campaigns needed in the face of an emerging influenza pandemic. While FLUPLAN addresses the technical development of the platform, including one of the promising candidate vaccines (MVA-based influenza A/H5N1 vaccine), ARCAS will focus on the commercial potential and the commercialization strategy for the platform. This will be achieved by conducting an extensive market study to determine the potential for the novel vaccine repository platform, by analyzing the IP position to build a solid IP portfolio, and by conducting a technical evaluation on the potential of the platform. This will provide the basis to determine the commercial potential and subsequently the most viable commercialization strategy for the platform, to be detailed in a strategic business plan. Furthermore, as part of the strategic business plan, we aim to develop a sound factsheet that will allow potential commercial partners to invest in the technology, addressing the current influenza market needs, given the competitive advantage offered by the platform.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores